PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Releases Update for U.S. Inflammatory Disease Drug Delivery - Survey finds future of drug delivery for inflammatory diseases is in the oral therapeutic market
Frost & Sullivan Releases Update for U.S. Inflammatory Disease Drug Delivery

 

NewswireToday - /newswire/ - Mountain View, CA, United States, 2010/12/21 - Survey finds future of drug delivery for inflammatory diseases is in the oral therapeutic market.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Frost & Sullivan updates study U.S. Inflammatory Disease Drug Delivery - Patient Perspective, which investigates physician and customer preferences and prescribing trends relative to drug delivery considerations for specific diseases - rheumatoid arthritis, Crohn's disease and psoriasis.

"With the exception of psoriasis, a majority of patients take oral medication for an inflammatory condition," states Jennifer Brice, industry manager for Frost & Sullivan. "Most patients are satisfied with taking an oral drug versus an injection or topical gel/cream. Oral drug delivery is most associated with ease of self-administration, the dominant consideration for selecting drug delivery types, as well as convenience and low cost."

If you are interested in more information on this study, please send an email to Johanna Haynes, Corporate Communications, at johanna.haynes[.]frost.com, with your full name, company name, title, telephone number, company email address, company website, city, state and country.

U.S. Inflammatory Disease Drug Delivery - Patient Perspective is a re-analysis of a 2008 study. This information encompasses feedback provided by U.S. patients on aspects of drug delivery for inflammatory diseases consisting of rheumatoid arthritis, Crohn's disease and psoriasis, enabling interested stakeholders to gain insight into current and future trends. Frost & Sullivan conducted a web-based survey of 110 U.S. inflammatory disease patients in Q4 2007 - January 2008.

Research Objectives are as follows:

• Identify drug delivery trends within specific disease areas;

• Determine product attributes relative to delivery that are considered important by patients;

• Identify prospective patient preferences and willingness to try new technologies as well as determine key drivers of adoption/non-adoption.

Respondents were asked about general awareness of drug delivery types, availability and usage, frequency of usage, satisfaction and reasons for satisfaction with method used, willingness and reasons for willingness to use, barriers for usage, and reasons for preference.

Although each drug delivery method is associated with unique benefits such as minimal or no discomfort and rapid onset of drug action, the future of drug delivery for inflammatory diseases is in the oral therapeutic market.

"Seventy-five percent of patients that use oral drug delivery for their psoriasis treatment are very satisfied/ satisfied versus only 55% of topical gel/cream users being very satisfied/ satisfied," observes Brice. "Reasons for satisfaction with the oral drug delivery method are easy to self administer (reported by 60% of patients), low cost (reported by 20% of patients) and convenience (reported by 20% of patients). Sixty-six percent of Crohn's disease patients and 91% of rheumatoid arthritis patients noted they are very satisfied/ satisfied with oral delivery use in their treatment."

This Frost & Sullivan research service entitled U.S. Inflammatory Disease Drug Delivery - Patient Perspective provides insight into ophthalmologists views on patient compliance with medication instructions, their considerations in selecting medications, and their opinions of various brands of medication. In this research, Frost & Sullivan's expert analysts thoroughly examine the following: patient compliance with eye care medication instructions, factors impacting prescriptions for eye care medications, and preferences for eye disease medications, including glaucoma medications in particular.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best-in-class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best-practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from 40 offices on six continents.

U.S. Inflammatory Disease Drug Delivery - Patient Perspective / N835-52

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Releases Update for U.S. Inflammatory Disease Drug Delivery

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

FDA Approves Genentech’s Actemra (Tocilizumab) for Giant Cell Arteritis
BTG and HealthLoop Collaborate on IO Loop™ - An Exclusive Service to Connect Patients and Interventional Oncologists throughout Treatment
BD and UniteOR Join Forces to Deliver an Integrated Tracking Solution for the Operating Room Setting
MDxHealth and Maastricht University Collaborate on Next Generation (Epi)genetic Cancer Diagnostics
BD to Invest $60 Million in Nebraska Manufacturing Facility
MDxHealth Announces New Contract with MediNcrease Health Plans Regarding ConfirmMDx and SelectMDx
Pulse Certified As A Level Four Multichannel Content Agency by Veeva
Earthly Mist - Opioid-Alternative Painkiller, Kratom Now Available in Oklahoma City
MDxHealth and Exact Sciences Sign Collaboration Agreement
BD Advances Efforts to Combat Antimicrobial Resistance with Enhanced Diagnostic Solution Offering
First European Patients Treated with DC Bead LUMI™ Radiopaque Drug-Eluting Beads
FDA Approves Genentech’s Lucentis (Ranibizumab Injection) for Diabetic Retinopathy
Biopharmaceutical Analytical Instrumentation Market Garners Strong Opportunities from Double-digit Growth in Biosimilars Finds Frost & Sullivan
BD Completes Acquisition of Caesarea Medical Electronics
MDxHealth and Ghent University Ink Licensing and Collaboration Agreements to Develop Cancer Biomarker Visualization Technology

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Intrinsic Executive Search Ltd

Visit  NAKIVO, Inc.





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)